Status:
COMPLETED
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes. The primary hypothesis of the study is that after 4 we...
Eligibility Criteria
Inclusion
- Subject has a diagnosis of type 2 diabetes and is being treated with diet and exercise alone, a single oral anti-hyperglycemic agent or a combination of two oral anti-hyperglycemic agents
- Subject is willing to follow a weight-maintaining diet and exercise program during the study
- Subject is a nonsmoker or is willing to limit smoking to 10 cigarettes per day while in the clinical research unit
Exclusion
- Subject has a history of stroke, chronic seizures, or major neurological disorder
- Subject has a history of cancer, except certain skin and cervical cancers or cancer that was successfully treated 10 or more years prior to screening
- Subject has a history of type 1 diabetes
- Subject has used contact lenses within the last 6 months
- Subject has used any lipid-lowering therapy in the last 3 months, except statins, Zetia, or Vytorin
- Subject has more than 3 alcoholic beverages per day
- Subject has more than 6 servings of caffeine a day
- Subject has participated in a previous MK8245 study
Key Trial Info
Start Date :
August 24 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 26 2010
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT00972322
Start Date
August 24 2009
End Date
January 26 2010
Last Update
September 10 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.